Biogen International GmbH

Biogen has been a pioneer in biotechnology for over two decades and today is a global organization with more than 7,000 employees. Biogen possesses a world-leading portfolio of medicines to treat multiple sclerosis, and is at the forefront of research into new medicines for neurological conditions and rare genetic disorders.

Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options. Biogen first became a Britest Associate in 2017 following a successful demonstration of value through a Britest facilitated four-day, end-to-end process review for a Biogen product.